Abstract

Many polymorphs of KFA-1982, an orally active factor Xa (fXa) inhibitor, have been identified and their physicochemical properties have been investigated. Form B was selected as the oral API form because of its superior stability and solubility characteristics. Crystallization conditions for form B were thoroughly investigated including the role of water in hydrate formation and the use of antisolvents and supersaturation in polymorph control.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call